Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: Results from the United States Registry for Fibromuscular Dysplasia

Vascular Medicine (United Kingdom)

Volumn 20, Issue 5, 2015, Pages 447-453

  Weinberg, Ido ^a   Gu, Xiaokui ^b   Giri, Jay ^c   Kim, Soo E ^d   Bacharach, Michael J ^e   Gray, Bruce H ^f   Katzen, Barry T ^g   Matsumoto, Alan H ^h   Chi, Yung Wei ⁱ   Rogers, Kevin R ^j   Froehlich, James ^b   Olin, Jeffrey W ^k   Gornik, Heather L ^d   Jaff, Michael R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e North Central Heart Institute   (United States)

^f UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE GREENVILLE   (United States)

^g BAPTIST CARDIAC AND VASCULAR INSTITUTE   (United States)

^h UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

anti platelet; fibromuscular dysplasia; FMD; hypertension; medication

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRAIN ARTERY; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COMORBIDITY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DRUG USE; FEMALE; FIBROMUSCULAR DYSPLASIA; HUMAN; HYPERTENSION; KIDNEY ARTERY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; AGED; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; REGISTER; RENAL ARTERY OBSTRUCTION; RENOVASCULAR HYPERTENSION; STATISTICS AND NUMERICAL DATA; THROMBOCYTE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PLATELETS; FEMALE; FIBROMUSCULAR DYSPLASIA; HUMANS; HYPERTENSION, RENOVASCULAR; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REGISTRIES; RENAL ARTERY; RENAL ARTERY OBSTRUCTION; UNITED STATES;

EID: 84943176426     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X15584982     Document Type: Article

References (16)

1. Olin JW, Froehlich J, Gu X, et al. The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation 2012; 125: 3182-3190.
2. Slovut DP, Olin JW,. Fibromuscular dysplasia. Curr Treat Options Cardiovasc Med 2005; 7: 159-169.
3. Pascual A, Bush HS, Copley JB,. Renal fibromuscular dysplasia in elderly persons. Am J Kidney Dis 2005; 45: e63-66.
4. Weinberg I, Jaff MR,. Nonatherosclerotic arterial disorders of the lower extremities. Circulation 2012; 126: 213-222.
5. Schievink WI,. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med 2001; 344: 898-906.
6. Olin JW, Sealove BA,. Diagnosis, management, and future developments of fibromuscular dysplasia. J Vasc Surg 2011; 53: 826-836.e1.
7. Giavarini A, Savard S, Sapoval M, Plouin PF, Steichen O,. Clinical management of renal artery fibromuscular dysplasia: temporal trends and outcomes. J Hypertens 2014; 32: 2433-2438.
8. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520.
9. Sperati CJ, Aggarwal N, Arepally A, Atta MG,. Fibromuscular dysplasia. Kidney Int 2009; 75: 333-336.
10. Murdoch DR,. Taking precautions with angiotensin converting enzyme inhibitors. Screening for unilateral renal artery stenosis cannot be justified. BMJ 1999; 318: 257-258.
11. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120: 1598-1605.
12. US Preventive Services Task Force. Aspirin for prevention of cardiovascular disease. Available at: www.uspreventiveservicestaskforce.org/uspstf/uspsasmi.htm (. accessed 10 February 2013).
13. Stanley JC, Gewertz BL, Bove EL, Sottiurai V, Fry WJ,. Arterial fibrodysplasia. Histopathologic character and current etiologic concepts. Arch Surg 1975; 110: 561-566.
14. Olin JW, Gornik HL, Bacharach JM, et al.; American Heart Association Council on Peripheral Vascular Disease, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, American Heart Association Council on Cardiovascular Disease in the Young, American Heart Association Council on Cardiovascular Radiology and Intervention, American Heart Association Council on Epidemiology and Prevention, American Heart Association Council on Functional Genomics and Translational Biology, American Heart Association Council for High Blood Pressure Research, American Heart Association Council on the Kidney in Cardiovascular Disease, American Heart Association Stroke Council. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation 2014; 129: 1048-1078.
15. Alonso-Coello P, Bellmunt S, McGorrian C, et al.; American College of Chest Physicians. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e669S-690S.
16. Lansberg MG, ODonnell MJ, Khatri P, et al.; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e601S-636S.